IHT Wealth Management’s Galectin Therapeutics GALT Stock Holding History

IHT Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-28,155	Closed	-$86K	–	671
2020 Q2	$86K	Buy	28,155 +10,000	+55%	+$25.2K	0.01%	564
2020 Q1	$36K	Hold	18,155	–	–	0.01%	542
2019 Q4	$52K	Hold	18,155	–	–	0.01%	613
2019 Q3	$67K	Buy	18,155 +2,075	+13%	+$7.5K	0.01%	594
2019 Q2	$67K	Hold	16,080	–	–	0.01%	529
2019 Q1	$82K	Buy	16,080 +5,550	+53%	+$26.6K	0.01%	494
2018 Q4	$36K	Buy	10,530 +500	+5%	+$2.39K	0.01%	469
2018 Q3	$60K	Buy	+10,030	New	+$55.2K	0.01%	419
2018 Q2	–	Sell	-6,780	Closed	-$28K	–	783
2018 Q1	$28K	Hold	6,780	–	–	0.01%	862
2017 Q4	$34K	Buy	6,780 +2,780	+70%	+$7.03K	0.01%	810
2017 Q3	$10K	Hold	4,000	–	–	﹤0.01%	967
2017 Q2	$23	Hold	4,000	–	–	0.01%	736
2017 Q1	$9K	Buy	4,000 +2,000	+100%	+$3.01K	0.01%	873
2016 Q4	$2K	Buy	+2,000	New	+$1.78K	﹤0.01%	1032

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

IHT Wealth Management's GALT Position: Q3 2020 in Review

IHT Wealth Management sold out of Galectin Therapeutics (GALT) in Q3 2020, closing a stake of 28,155 shares — an estimated $86K sold.

IHT Wealth Management first reported a position in GALT in Q4 2016 and held it in 14 quarters. The position peaked at $86K in Q2 2020. 71 funds tracked by Wall St. Rank hold GALT as of Q3 2020.

IHT Wealth Management reported no remaining Galectin Therapeutics position as of Q3 2020 after selling out during the quarter.
IHT Wealth Management sold 28,155 Galectin Therapeutics shares in Q3 2020, an estimated $86K.
IHT Wealth Management first reported a position in Galectin Therapeutics in Q4 2016 and held it in 14 quarters.
IHT Wealth Management's Galectin Therapeutics position peaked at $86K in Q2 2020.
71 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2020.

Based on IHT Wealth Management's 13F filing for Q3 2020, filed 19 Nov 2020.